Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso

Tropical Medicine and International Health

Volumn 10, Issue 1, 2005, Pages 32-38

  Mandi, Germain ^a   Witte, Steffen ^b   Meissner, Peter ^b   Coulibaly, Boubacar ^a   Mansmann, Ulrich ^b   Rengelshausen, Jens ^b   Schiek, Wolfgang ^c   Jahn, Albrecht ^b   Sanon, Mamadou ^a   Wüst, Kirsten ^b   Walter Sack, Ingeborg ^b   Mikus, Gerd ^b   Burhenne, Jürgen ^b   Riedel, Klaus Dieter ^b   Schirmer, Heiner ^b   Kouyaté, Bocar ^a   Müller, Olaf ^b  

^a Nouna Health Research Centre   (Burkina Faso)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DSM Fine Chemicals Austria Nfg GmbH & Co KG   (Netherlands)

Author keywords

Africa; G6PD deficiency; Malaria; Methylene blue

Indexed keywords

CHLOROQUINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HEMOGLOBIN; METHYLENE BLUE;

MALARIA;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; AGED; ARTICLE; BURKINA FASO; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDEMIC DISEASE; GASTROINTESTINAL DISEASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HAND INJURY; HEADACHE; HEMOLYSIS; HUMAN; HUMAN EXPERIMENT; INTOXICATION; MALARIA; MALARIA FALCIPARUM; MALE; NEUROLOGIC DISEASE; NORMAL HUMAN; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RURAL AREA; STATISTICAL ANALYSIS; VOLUNTEER; VOMITING;

ADOLESCENT; ADULT; ANTIMALARIALS; CHLOROQUINE; DRUG THERAPY, COMBINATION; GLUCOSEPHOSPHATE DEHYDROGENASE DEFICIENCY; HEMATOCRIT; HEMOGLOBINS; HEMOLYSIS; HUMANS; MALARIA, FALCIPARUM; MALE; METHYLENE BLUE; MIDDLE AGED; RURAL HEALTH;

EID: 19944431407     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01356.x     Document Type: Article

References (34)

1. Amaral L, Viveiros M & Kristiansen JE (2001) Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Tropical Medicine and International Health 6, 1016-1022.
2. Beutler E & Mitchell M (1968) Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. Blood 32, 816-818.
3. Bloland PB, Ettling M & Meek S (2000) Combination therapy for malaria in Africa: hype or hope? Bulletin of the World Health Organisation 78, 1378-1388.
4. Brewer GJ, Tarlov AR & Alving AS (1962) The methemoglobin reduction test for primaquine-type sensitivity of erythrocytes. A simplified procedure for detecting a specific hypersusceptibility for drug hemolysis. JAMA 180, 386-388.
5. Coulibaly B (2004) Malaria-related studies on enzymopathies, methemoglobin, and methylene blue. PhD Thesis, Heidelberg University, Germany.
6. CPMP (1997) Note for Guidance on Clinical Investigation of Medicinal Products in Children. CPMP/EWP/462/95 (Available at: http://www.emea.eu.int/ pdfs/human/ewp/046295en.pdf).
7. Dorsey G, Njama D, Kamya MR et al. (2002) Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. The Lancet 360, 2031-2038.
8. Ehrlich P (1913) Chemotherapeutics: scientific principles, methods, and results. The Lancet ii, 445-451.
9. Färber PM, Arscott LD, Williams CH, Becker K & Schirmer RH (1998) Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Letters 422, 311-314.
10. Ferreira C (1893) Sur l'emploi du bleu de méthylène dans la malaria infantile. Revue de Thérapeutique Médico-Chirugicale 1893, 488-525.
11. Fleming AF & de Silva PS (2003) G6PD deficiency. In: Manson's Tropical Diseases (eds GC Cook & A Zumla) Elsevier Science Ltd, Edinburgh, pp. 208-212.
12. Gasasira AF, Dorsey G, Nzarubara B et al. (2003) Comparative efficacy of amodiaquine-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. American Journal of Tropical Medicine and Hygiene 68, 127-132.
13. Goluboff N & Wheaton R (1961) Methylene blue induced cyanosis and acute haemolytic anemia complicating the treatment of methemoglobinaemia. Journal of Pediatrics 58, 86-89.
14. Greenwood B & Mutabingwa T. (2002) Malaria in 2002. Nature 415, 670-672.
15. Greenwood B, Bradley A, Greenwood A et al. (1987) Mortality and morbidity from malaria among children in a rural area of The Gambia. Transactions of the Royal Society of Tropical Medicine and Hygiene 81, 478-486.
16. Guttmann P & Ehrlich P (1891) Über die Wirkung des Methylenblau bei Malaria. Berliner Klinische Wochenschrift 28, 953-956.
17. International Artemisinin Study Group (2004) Artesunate combinations for treatment of malaria: meta-analysis. The Lancet 363, 9-17.
18. Lang T & Greenwood B (2003) The development of Lapdap, an affordable new treatment for malaria. The Lancet Infectious Diseases 3, 162-168.
19. Meierjohann S, Walter RD & Müller S (2002) Regulation of intracellular glutathione levels in erythrocytes infected with chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum. Biochemical Journal 368, 762-768.
20. Müller O, Becher H, Baltussen A et al. (2001) Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomized double blind placebo controlled trial. British Medical Journal 322, 1567-1572.
21. Müller O, Traoré C, Kouyaté B & Becher H (2003a) Malaria morbidity, treatment seeking behaviour, and mortality in a cohort of young children in rural Burkina Faso. Tropical Medicine and International Health 8, 290-296.
22. Müller O, Traoré C & Kouyaté B (2003b) Clinical efficacy of chloroquine in young children with uncomplicated malaria - a community based study in rural Burkina Faso. Tropical Medicine and International Health 8, 202-203.
23. Nosten F & Brasseur P (2002) Combination therapy for malaria. Drugs 62, 1315-1329.
24. Ruwende C & Hill A (1998) Glucose-6-phosphate dehydrogenase deficiency and malaria. Journal of Molecular Medicine 76, 581-588.
25. Rwangacondo C, Niyitegeka F, Sarushi J et al. (2003) Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. American Journal of Tropical Medicine and Hygiene 68, 743-747.
26. Scheiwein M (2001) Pathophysiologische und chemotherapeutische Mechanismen der Glutathionreduktase-Inaktivierung bei Malaria. MD thesis, Heidelberg University, Germany.
27. Schirmer RH, Coulibaly B, Stich A et al. (2003) Methylene blue as an antimalarial agent. Redox Report 8, 272-276.
28. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials 10, 1-10.
29. Snow RW, Craig M, Deichmann U & Marsh K (1999) Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bulletin of the World Health Organisation 77, 624-640.
30. Trape J (2001) The public health impact of chloroquine resistance in Africa. American Journal of Tropical Medicine and Hygiene 64 (Suppl.), 12-17.
31. Vennerstrom JL, Makler MT, Angerhofer CK & Williams JA (1995) Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrobial Agents and Chemotherapy 39, 2671-2677.
32. White NJ, Nosten F, Looareesuwan S et al. (1999) Averting a malaria disaster. The Lancet 353, 1965-1967.
33. WHO (1997) World malaria situation in 1994. Weekly Epidemiological Record 72, 269-292.
34. Winstanley P (2001) Modern chemotherapeutic options for malaria. The Lancet Infectious Diseases 1, 242-250.